CompletedPhase 1NCT03163121

Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers

Studying Malaria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sanaria Inc.
Principal Investigator
Robert W. Sauerwein, MD
Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
Intervention
PfSPZ-GA1 Vaccine(biological)
Enrollment
67 target
Eligibility
18-35 years · All sexes
Timeline
20172018

Study locations (2)

Collaborators

Radboud University Medical Center · Leiden University Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03163121 on ClinicalTrials.gov

Other trials for Malaria

Additional recruiting or active studies for the same condition.

See all trials for Malaria

← Back to all trials